Dr. Foley has a long-standing research interest in protein homeostasis and the ubiquitin-proteasome system, which he has continued as co-founder and CSO of Ranok Therapeutics, a clinical-stage biopharmaceutical company that is pioneering a novel approached to targeted protein degradation, Chaperone-mediated protein degradation (CHAMP®) for the treatment of cancer and other serious diseases.He has 25 years’ experience in drug discovery, preclinical and clinical development, with an emphasis on cancer, immuno-oncology and autoimmune diseases. In prior roles at FORMA Therapeutics, GlaxoSmithKline, Synta Pharmaceuticals, Millennium Pharmaceuticals and ZymoGenetics he has had a successful track record of advancing innovative therapies into the clinic. He was a postdoctoral fellow at the Fred Hutchinson Cancer Research Center, and received his Ph.D. in Molecular Biology at Northwestern University and a B.S. in Biochemistry at Michigan State University.He has also served as a grant reviewer for NIH, BARDA and Boston University, as well as a member of the Scientific Advisory Board for a biotech startup and an advisor for the careers website of the journal Science.Dr. Foley has authored 32 publications and has 32 issued US patents.Expertise: Biomarkers, cancer / oncology, discovery / preclinical / clinical development, immunology / inflammation, in vivo pharmacology, orphan diseases, translational research